VivoSeq
Oncology

Grade 1 Follicular Lymphoma

8

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Grade 1 Follicular Lymphoma is an early-stage landscape with 8 programs across 6 companies. The most active players are SymBio Pharmaceuticals, Gynecologic Oncology Group, Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SymBio Pharmaceuticals

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Roche logo

Roche

1 program

Phase 2T

TG Therapeutics, Inc.

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03269669·73 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)